About Good Biotech

Good Biotech Corp., an unprecedented duck IgY(ΔFc) antibody inventor and diagnostics manufacturer, has successfully built up the proprietary technology platform by using ducks as bioreactors to produce and develop novel polyclonal IgY(ΔFc) antibodies into various Biotechnology as well as biotherapeutics applications, including Immunodiagnostics, IgY(ΔFc) antibody derived therapeutic antibodies, oral-administration nutraceuticals, food for specific health use (FOSHU), and anti-caries oral healthcare products. We are the only company with the capability to rapidly mass production duck IgY(ΔFc) antibodies from hyper-immune duck eggs on an industrial scale.

Good Biotech, also a professional polyclonal antibody manufacturer, has supplied quality polyclonal antibodies to worldwide customers for 40 years. Good Biotech acquired NBL Biochemical Corp. (NBL) and was founded in 1998. NBL was the leading and only polyclonal manufacturer in Taiwan and had been offered polyclonal antibodies to the IVD industry, especially to Japan, the United States, and Europe Union for decades.

We are the very first company to successfully develop and commercialize avian-antibody-based immunodiagnostic assay kits, certified by FDA 510(k) (USA) and CE Marking (Europe). Thanks to the unique characteristics of the duck IgY(ΔFc) antibody, these new generation antibody-based immunodiagnostic kits have been recognized by our customers to be the highest quality range of routine and novel diagnostic reagents in the world. Having the advantages such as being free from common interferences, the performance including the sensitivity, precision, and accuracy can be greatly improved by using duck IgY(ΔFc) antibodies as the materials of immunodiagnostic reagents; therefore, the performance of the kits is much superior to most of the current diagnostics kits that are made from mammalian antibodies on the market.

 


Research and Development

Good Biotech is dedicated to continuously improving our products and developing innovative solutions to address unmet medical needs.

The technology platform for production and the applications of duck IgY(ΔFc) antibodies is solely owned by Good Biotech Corp. and the patents have been granted worldwide including all the major and dominant markets. This proprietary technology has been successfully applied to biotherapeutic applications that address high unmet medical needs: IgY(ΔFc) Antibody derived Biotherapeutics. We have gained promising achievements in the development of duck IgY(ΔFc) antibody derived Snake Antivenom immunoglobulins, Digoxin Immune Fab (for the treatment of digoxin envenomation & severe preeclampsia), Neutralizing IgY(ΔFc) Antibodies to Multidrug-Resistant (MDR) Bacterial Infections (e.g., pathogenic P. aeruginosa, Tuberculosis), anti-Obesity Nutraceuticals, Food for Specific Health Use (FOCHU), and anti-Caries, Gastrointestinal Health Care (e.g., Norovirus, H. pylori, Enterovirus, Rotavirus)Products.

• Co-Development anti-SARS IgY(ΔFc) antibody with Academia Sinica

From the Co-Development Project with Academia Sinica, Good Biotech used its patented technologies to produce duck anti-SARS CoV IgY(ΔFc) antibody and according to the evaluation made by Academia Sinica, the neutralization efficacy was excellent. The studies also indicated that the production of hyperimmune IgY(ΔFc) antibodies of new emergence pathogens by immunizing recombinant viral proteins to ducks has the potential to become a reliable approach for the treatment of infections in clinical emergencies.

Production of duck IgY(ΔFc) antibody-derived biotherapeutics are cost-effective, conforming to the expectation of animal protection organizations, and is timely in view of the World Health Organization (WHO)'s current initiative to review the quality, efficacy, and safety of biologicals.


IgY(ΔFc) Ab derived New Generation Immunoturbidimetric Assays

Good Biotech is focused on creating innovative diagnostic solutions that enable effective diagnosis and improve healthcare.

Good Biotech's new generation duck IgY(ΔFc) antibody-based immunoturbidimetric assays (with FDA 510(k) cleared/CE Marked), according to our customers’ reports,  are one of the best in the world that with the highest quality and are far superior to those traditional mammalian IgG antibodies based LIT assay reagents (latex-enhanced immunoturbidimetric assays) or luminescence-based immune-assays. Because of the excellent performance of the new assays, Good Biotech was invited by US CDC to join a project of standardization of hsCRP assays “Standardization of Immunoassays for Measurement of High-Sensitivity C-reactive Protein. (Phase I): Evaluation of Secondary Reference Materials” (Clinical Chemistry) and was one of the four latex-enhanced immunoturbidimetric assays’ manufacturers participated.

Good Biotech Point of Care Testing is aim to offer innovative solutions to help both healthcare professionals and patients achieve the best possible outcome with effective diagnosis and provide the best quality patient care

Good Biotech’s Whole Blood CRP LIT Assay for POCT, developed for the quantitative measurement of CRP in human whole blood, serum, or plasma, is easy-to-use and able to obtain more rapid, accurate, precise, and reliable test results within 2-3 minutes. The Whole Blood CRP LIT Assay for POCT is an excellent tool for use in the physician's office, hospital bedside, the intensive critical care unit (ICU), emergency department (ED) as well as in the central lab, that is inside or outside the hospital.

Good Biotech's newly launched: New Generation Duck IgY(ΔFc) Antibody derived Snake Venom POCT Kit, a One-Step, Visual Snake Venom Rapid Test Kit, enables victims/healthcare professionals to more quickly specific diagnosis (within minutes) compared to current methods (complex/laborious). Snakebite is an acute life-threatening time-limiting medical emergency. Antivenom is the treatment for serious snake envenomation. The sooner antivenom can be started, the sooner irreversible damage from venom can be stopped. Good Biotech's Snake Venom POCT kit is a ready-to-use kit and is intended for rapid diagnosing snake toxins for envenomed patients, providing immediate results (identifying the snake precisely) and thus allowing treatment decisions to be made more quickly. This new generation duck IgY(ΔFc) antibody-derived snake venom POCT kit is one of kind: a simple, convenient, reliable, affordable, effective rapid immunodiagnostic test allowing the toxins to be identified unambiguously. The kit is NO instrument needed, NO electricity needed, and is especially suitable for medical emergency use even for the poor rural areas in developing countries where medical resources, healthcare professionals, water, and electricity are often sparse.


Business Focus Areas

  • Diagnostics: Immunodiagnostic Assays and Immunochemistry: Turbidimetric immunoassay and latex-enhanced immunoturbidimetry assay for use in general clinic chemistry auto-analyzers.
  • Point of Care Testing (POCT): Good Biotech Point of Care Testing (POCT) provides quantitative determination, easy-to-use point-of-care solutions and is intended for use by healthcare professionals inside or outside the hospital. Good Biotech point-of-care solutions deliver accurate and immediate results, allowing treatment decisions to be made more quickly outside the central lab.
  • The development of IgY(ΔFc) antibody derived Biotherapeutics: including Antivenoms, Antitoxins, Antidotes, Neutralizing IgY(ΔFc) antibodies to MDR bacteria, and the specialist Biologicals used in emergency rooms, ICUs as critical care products.
  • The development of IgY(ΔFc) antibody-derived oral-administration Nutraceuticals, Functional Health Foods, and oral Health, Skin Healthcare products.
  • IgY(ΔFc) antibody derived Depletion Column products and R&D of Life Science products.